HomeQuestion

For women with known autoimmune diseases, how do you approach ASCVD risk stratification when deciding to start a statin or aspirin for primary prevention?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

When would you consider switching to or adding on a PCSK9 inhibitor to lipid-lowering therapy following hospital discharge for acute coronary syndrome, in light of the results of the VICTORION-INCEPTION trial, provided LDL is still not at goal?

When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?

What advice would you give to patients who are concerned about statin use and its controversies around brain health and dementia risk, based on previous studies?

What are your top takeaways for the 2026 ACC/AHA lipid guidelines?

Would you measure apolipoprotein B in addition to lipoprotein A to guide statin initiation in a younger patient whose PREVENT ASCVD risk falls near a treatment threshold?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.